Rubius Therapeutics Performance
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
The company holds a Beta of 1.73, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rubius Therapeutics will likely underperform. Rubius Therapeutics right now holds a risk of 0.0%. Please check Rubius Therapeutics maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Rubius Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rubius Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Rubius Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 227.6 M |
Rubius |
Rubius Therapeutics Relative Risk vs. Return Landscape
If you would invest 8.30 in Rubius Therapeutics on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Rubius Therapeutics or generate 0.0% return on investment over 90 days. Rubius Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Rubius, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rubius Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rubius Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Rubius Therapeutics, and traders can use it to determine the average amount a Rubius Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RUBY |
Based on monthly moving average Rubius Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rubius Therapeutics by adding Rubius Therapeutics to a well-diversified portfolio.
Rubius Therapeutics Fundamentals Growth
Rubius Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rubius Therapeutics, and Rubius Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rubius Pink Sheet performance.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Cash And Equivalents | 140.71 M | |||
| Cash Per Share | 1.56 X | |||
| Total Debt | 76.15 M | |||
| Debt To Equity | 1.17 % | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (150.14 M) | |||
| Earnings Per Share | (2.27) X | |||
| Total Asset | 23.07 M | |||
About Rubius Therapeutics Performance
Evaluating Rubius Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Rubius Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rubius Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of patients with severe diseases. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Rubius Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 213 people.Things to note about Rubius Therapeutics performance evaluation
Checking the ongoing alerts about Rubius Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rubius Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rubius Therapeutics is not yet fully synchronised with the market data | |
| Rubius Therapeutics has some characteristics of a very speculative penny stock | |
| Rubius Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (179.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rubius Therapeutics currently holds about 140.71 M in cash with (150.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors |
- Analyzing Rubius Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rubius Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rubius Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rubius Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rubius Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rubius Therapeutics' pink sheet. These opinions can provide insight into Rubius Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |